Farnesoid X Receptor to Reduce Neuroinflammation
Target Validation Award, 2017
Although the precise mechanism(s) for neurodegeneration in Parkinson's disease (PD) is unknown, evidence suggests that neuroinflammation is an important contributor. In this study, we will use pre-clinical models of PD to determine whether existing drugs targeting the farnesoid x receptor, protein that regulates metabolism, can reduce inflammation and protect dopamine neurons.
This study hypothesizes that drugs targeting the farnesoid x receptor that are currently in clinical trials for other purposes will reduce neuroinflammation in pre-clinical models of Parkinson's.
We will use two pre-clinical models of PD that both have significant inflammatory components. Existing drugs/compounds that target the farnesoid x receptor will be administered to determine whether they can reduce inflammation and protect dopamine neurons from dying.
Next Steps for Development:
If our experiments are successful, these drugs may progress to clinical trials for Parkinson's more rapidly, as they have been in clinical trials for other conditions.
Professor of Pharmaceutical Sciences, Founding Director of Neurodegenerative Disease and Aging Research Focus Area, Acting Associate Dean for Research at Northeast Ohio Medical University
Location: Rootstown, Ohio, United States